NEW YORK, NY (Jan. 24, 2018)—A paper published today in the New England Journal of Medicine reports that solanezumab, a monoclonal antibody-based treatment for Alzheimer’s disease developed by Eli Lilly that targets amyloid plaques, did not significantly slow cognitive decline.
Researchers have proposed that Alzheimer’s disease is caused by the buildup of a sticky protein called beta-amyloid. According to this “amyloid hypothesis,” the protein forms plaques in the brain that damage and eventually destroy brain cells. Solanezumab was designed to reduce the level of soluble amyloid molecules before they aggregate.
A total of 2,129 patients with mild dementia due to Alzheimer’s disease participated in the double-blind, placebo-controlled, phase 3 multicenter trial. This study was the first major Alzheimer’s clinical trial to require molecular evidence of amyloid deposition in the brain for enrollment. While the treatment did have some favorable effects, in the main measure of outcome—measured with a cognitive test called the Alzheimer’s Disease Assessment Scale-cognitive subscale—the researchers did not observe any statistically significant benefit compared with placebo.
The authors suggest that while it is not certain that this particular strategy or drug could be effective, it is possible that either not enough drug was administered or that the drug needs to be administered earlier in the disease course.
In other studies ongoing at Columbia University Irving Medical Center and other centers, solanezumab is being evaluated in presymptomatic patients at risk of Alzheimer’s disease. Other Alzheimer’s drugs are also in development and being tested at higher doses.
“Although we are disappointed that this particular drug did not prove successful, the field is benefiting from each study,” says lead author Lawrence Honig, MD, PhD, professor of neurology at CUIMC. “There is hope that one of the newer ongoing studies may result in an effective treatment for slowing the course of Alzheimer’s disease.”
The results of this study were first released in late 2016 and presented by Dr. Honig at the 10th Clinical Trials on Alzheimer’s Disease international meeting in San Diego.
The study is titled “Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease.”
Additional authors are Bruno Vellas, MD, Michael Woodward, MD, Merc. Boada, MD, PhD, Roger Bullock, MD, Michael Borrie, MB, ChB., Klaus Hager, MD, Niels Andreasen, MD, PhD, Elio Scarpini, MD, Hong Liu‑Seifert, PhD, Michael Case, MS, Robert A. Dean, MD, PhD, Ann Hake, MD, Karen Sundell, BS, Vicki Poole Hoffmann, PharmD, Christopher Carlson, PhD, Rashna Khanna, MD, Mark Mintun, MD, Ronald DeMattos, PhD, Katherine J. Selzler, PhD, and Eric Siemers, MD. Their affiliations are listed in the appendix of the paper.
The study was designed and funded by Eli Lilly and Company. The authors report additional conflicts of interest in the manuscript.
Columbia University Irving Medical Center provides international leadership in basic, preclinical, and clinical research; medical and health sciences education; and patient care. The medical center trains future leaders and includes the dedicated work of many physicians, scientists, public health professionals, dentists, and nurses at the College of Physicians and Surgeons, the Mailman School of Public Health, the College of Dental Medicine, the School of Nursing, the biomedical departments of the Graduate School of Arts and Sciences, and allied research centers and institutions. Columbia University Irving Medical Center is home to the largest medical research enterprise in New York City and State and one of the largest faculty medical practices in the Northeast. For more information, visit cumc.columbia.edu or columbiadoctors.org.